Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | PIK3CA |
| Variant | H1047Y |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | PIK3CA H1047Y is a hotspot mutation that lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). H1047Y confers a gain of function on the Pik3ca protein as indicated by increased phosphorylation of Akt, activation of downstream signaling, and is transforming in cell culture (PMID: 17376864, PMID: 29533785). |
| Associated Drug Resistance | |
| Category Variants Paths |
PIK3CA mutant PIK3CA act mut PIK3CA H1047Y PIK3CA mutant PIK3CA exon21 PIK3CA H1047X PIK3CA H1047Y |
| Transcript | NM_006218.4 |
| gDNA | chr3:g.179234296C>T |
| cDNA | c.3139C>T |
| Protein | p.H1047Y |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_006218 | chr3:g.179234296C>T | c.3139C>T | p.H1047Y | RefSeq | GRCh38/hg38 |
| NM_006218.4 | chr3:g.179234296C>T | c.3139C>T | p.H1047Y | RefSeq | GRCh38/hg38 |
| XM_006713658.5 | chr3:g.179234296C>T | c.3139C>T | p.H1047Y | RefSeq | GRCh38/hg38 |
| NM_006218.3 | chr3:g.179234296C>T | c.3139C>T | p.H1047Y | RefSeq | GRCh38/hg38 |
| XM_011512894.2 | chr3:g.179234296C>T | c.3139C>T | p.H1047Y | RefSeq | GRCh38/hg38 |
| XM_011512894 | chr3:g.179234296C>T | c.3139C>T | p.H1047Y | RefSeq | GRCh38/hg38 |
| XM_006713658 | chr3:g.179234296C>T | c.3139C>T | p.H1047Y | RefSeq | GRCh38/hg38 |
| XM_006713658.4 | chr3:g.179234296C>T | c.3139C>T | p.H1047Y | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA H1047Y | endometrial cancer | sensitive | MEN1611 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, MEN1611 (CH5132799) inhibited cell growth in a human endometrial cancer cell line harboring a PIK3CA H1047Y mutation, and inhibited tumor growth in xenograft models (PMID: 21558396). | 21558396 |
| PIK3CA H1047Y | glioblastoma | sensitive | YM-024 | Preclinical | Actionable | In a preclinical study, glioblastoma cell lines harboring PIK3CA H1047Y demonstrated increased sensitivity to YM-024 induced growth inhibition (PMID: 24718026). | 24718026 |